Robert W. Baird Cuts Medpace (NASDAQ:MEDP) Price Target to $477.00

Medpace (NASDAQ:MEDP) had its target price reduced by investment analysts at Robert W. Baird from $565.00 to $477.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 21.24% from the stock’s previous close.

MEDP has been the topic of a number of other reports. Leerink Partners dropped their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their target price for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Barclays set a $450.00 target price on shares of Medpace in a research report on Friday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday, February 13th. Finally, Truist Financial dropped their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $475.25.

Medpace Trading Down 22.6%

Shares of MEDP opened at $393.42 on Friday. Medpace has a twelve month low of $284.10 and a twelve month high of $628.92. The firm’s fifty day simple moving average is $470.96 and its 200-day simple moving average is $536.55. The firm has a market capitalization of $11.24 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 2.39 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 149.31%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts predict that Medpace will post 17.05 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MEDP. NewEdge Advisors LLC grew its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Medpace during the 2nd quarter worth $296,000. Finally, M&T Bank Corp grew its position in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat on sales and earnings: Medpace posted $706.6M revenue (+26.5% YoY) and $4.28 GAAP EPS, each above consensus, showing continued top-line growth and margin strength. This supports the company’s long-term profitability thesis. Earnings Transcript
• Neutral Sentiment: Backlog conversion outlook vs. cancellations: Management said roughly $1.94B of backlog is expected to convert in the next 12 months — a positive indicator for near-term revenue — but also noted rising cancellations, which clouds forward visibility. Investors will watch conversion cadence closely. Backlog Conversion Article
• Neutral Sentiment: FY2026 guidance maintained but not clearly above street: Medpace maintained EPS guidance of $16.68–$17.50 and revenue near $2.8B–$2.9B; the EPS range slightly brackets consensus, leaving room for debate whether guidance is conservative or disappointing. Press Release
• Negative Sentiment: Booking weakness — book-to-bill below 1.0: Net new business awards were $618.4M in Q1, producing a net book-to-bill of ~0.88x, signaling bookings lagging billed revenue and stoking concerns about near-term demand sustainability. That was the primary driver of the sharp share decline. Investor Coverage of Booking Miss
• Negative Sentiment: Leadership change disclosed: The company disclosed President Jesse Geiger plans to retire effective May 31, 2026, with the CEO temporarily reassuming the role — an unexpected governance change that added to investor uncertainty. QuiverQuant Report
• Negative Sentiment: Multiple securities class-action notices filed: Several law firms have announced investigations and class-action filings tied to alleged misstatements about growth and bookings; potential litigation is a headline risk and could pressure sentiment. Class Action Notice Investor Deadline Notice

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.